Convalescent plasma as a treatment for high-risk outpatients administered within 7 days after COVID-19 disease onset (CoV-Early)

Project description The CoV-Early study investigates whether plasma administration of ex-corona patients leads to a faster recovery in corona patients who have not yet been admitted to hospital. Because previous research in the Netherlands showed no benefit from treatment with plasma at a later stage of the disease (in hospital), we administer it quickly in this study (at the latest seven days after the onset of the disease). Research In this study, one group of patients will receive plasma with antibodies and a second group, the control group, will receive plasma without antibodies against the coronavirus. This is necessary in order to be able to reliably investigate the effectiveness of plasma. To participate, a patient must be at least 70 years old or 50 to 69 years old and also belong to a risk group. The study is coordinated by Erasmus MC and LUMC and was set up in collaboration with Sanquin.